Dr Stephanie Bewick

Dr Stephanie Bewick

Company: Destiny Pharma

Job title: Chief Business Officer


Introduction to NTCD-M3 10:00 am

• Highly statistically significant results in Phase 2 sets it apart from competitors • NTCD-M3 is a single strain so facilitates manufacture and low cost of goods • Being prepared for Phase 3 • Expected market positioning • Introduction to SPOR-COV • What it is and development plansRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.